Serena under fire for promoting GLP-1 drug during Super Bowl ads
For years. Big Pharma's Super Bowl presence was limited to brand awareness and avoiding anything that came across as a clinical claim. That has changed this year. Reports suggest, Super Bowl ad inventory for 2026 averaged $8 million per 30-second spot, with premium placements exceeding $10 million.
A video of ace tennis star Serena Williams showing off her weight loss during a super bowl advertisement promoting glp-1 medication is now going viral.
The retired tennis superstar credits her initial 2st 3lbs (14kg) drop by using Zepbound, which was provided by telehealth company Ro.
In the super bowl advertisement for telehealth company Ro, Williams is shown using an injectable pen device and navigating the company’s mobile app.
The campaign has drawn flak with observers saying that an A class athlete has pubicly endorsed what is largely seen as a problematic shortcut to lose weight.
There is conflict of interest as well given that her husband, Alexis Ohanian, is an investor in Ro and serves on its board.
Williams had in the past revealed she had been using the medication in partnership with the company, who focus on weight management after her second pregnancy.
For years. Big Pharma’s Super Bowl presence was limited to brand awareness and avoiding anything that came across as a clinical claim. That has changed this year.
Reports suggest, Super Bowl ad inventory for 2026 averaged $8 million per 30-second spot, with premium placements exceeding $10 million.
Novo’s 90-second spot has comedian and SNL stalwart Kenan Thompson announcing the new Wegovy pill.
A Hims & Hers Health commercial features a voiceover by rapper Common with the tag line "Rich People Live Longer."